GBA PRESENTS- the public games

Discussion in 'Stocks' started by stonedinvestor, Jul 22, 2024.

  1. GBAUpgrade-->CTLP Cantaloupe, Inc.-

    $10.78 0.43 (+4.15%)2:25 PM 02/25/25
    NASDAQ | $USD | Realtime

    Cantaloupe working with bankers to explore options, Reuters reports 14:17 Read More CTLP
     
    #8611     Feb 25, 2025
    TrailerParkTed likes this.
  2. Workday options imply 8.4% move in share price post-earnings » 14:34 WDAY

    believe we have this as short report material have to double check
     
    #8612     Feb 25, 2025
  3. hit $53 twice....

    Joyy price target raised to $57.10 from $46 at Jefferies » 12:58 YY, BIDU Jefferies a
     
    #8613     Feb 25, 2025
  4. Trade Desk named programmatic partner of Netflix amid ad offering expansion » 14:49 TTD
     
    #8614     Feb 25, 2025
  5. OpCo reiterates Outperform on Fulcrum given bullish vibes ahead of SCD readout » 14:00 FULC

    this dropped hard from$8 oct 24'

    they give out a lot of options that seem to count as insider buying but is it? Not when the shares are free/

    still bullish vibes are worth following...

    303,000 vol wait for a 1 mil vol day


    watch-->FULC Fulcrum Therapeutics, Inc.


    $3.71 0.01(+0.27%)2:50 PM 02/25/25
     
    #8615     Feb 25, 2025
  6. Oppenheimer analyst Matthew Biegler met with Fulcrum Therapeutics (FULC)’ management Tuesday after the company reported year-end financials. The last sickle cell patient has now been enrolled into the first dose expansion cohort, setting up for an important readout mid-year. Based on earlier results, the firm thinks a 7%-10% absolute improvement in HbF is doable and would position pociredir as the first oral drug since hydroxyurea with the ability to modify disease. VOC data will likely be premature, given the three-month follow-up-however, Fulcrum is enrolling sick patients here, so some directionality on that would be excellent to see, Oppenheimer argues. Assuming no safety concerns, advancement into the 20 mg arm remains on track for a year-end readout. The firm reiterates an Outperform rating on the shares with a price target of $14.
     
    #8616     Feb 25, 2025
  7. chicken & bird flu vaccine maker upside bias alert***********
    ZTS Zoetis Inc.
    $168.32
    +$3.01(+1.82%)3:02 PM 02/25/25
    NYSE |$USD |Realtime

    Market down / Stock Up
     
    #8617     Feb 25, 2025
  8. In this dystopian world we have been thrust by some angry idiots. Now everything falls apart, more plane drama; this is a very close call. Frump will be known for the falling stock market and the planes crashing.
     
    #8618     Feb 25, 2025
  9. #8620     Feb 25, 2025
    TrailerParkTed likes this.